The difference between domestic and imported versions of Valganciclovir: price and effect comparison

Valganciclovir is an antiviral drug mainly used to treat infections caused by human cytomegalovirus (CMV), especially for patients with suppressed immune function, such as patients after organ transplantation, AIDS patients, etc. Valganciclovir can be converted into ganciclovir in the body, which is a known effective anti-CMV drug. Indications for Vancevir include the prevention and treatment of CMV retinitis, the prevention of CMV infection in high-risk patients undergoing organ transplantation, and the management of CMV-related conditions in HIV-infected patients.

Regarding the difference between domestically produced and imported versions, imported Vancevir is currently on the Chinese market, but domestic generics have not yet been launched. In terms of price, the price of imported Vancevir is relatively high. Taking the specification of 0.45g*60 tablets as an example, the latest price has exceeded RMB 10,000, which is a considerable financial burden for many patients. Since there are no domestic alternatives on the market yet, patients mainly rely on imported drugs when taking medications, resulting in continued pressure on their financial burden.

In terms of effectiveness, the imported Vancevir has been verified through rigorous clinical trials, and its efficacy and safety have been widely recognized by the international medical community. Due to the lack of corresponding domestic generic drugs, patients face relatively limited choices. When purchasing imported drugs, they may need to consider potential risks arising from factors such as the source and transportation of the drugs. In the absence of domestic generic drugs, patients can only rely on imported drugs, which may affect the continuity of treatment due to drug prices during their long-term treatment.

In conclusion, valganciclovir, as an important antiviral drug, has significant clinical value in the treatment of human cytomegalovirus infection. However, since there are currently only imported versions on the market and are not covered by medical insurance, patients face challenges between affordability and continuity of treatment.

Reference materials:https://go.drugbank.com/drugs/DB01610